Cancer metastasis as a therapeutic target
Section snippets
Conflict of interest statement
None declared.
Acknowledgements
J.P.S. gratefully acknowledges funding from the European Union under the auspices of the FP7 collaborative project TuMIC, Contract No. HEALTH-F2-2008-201662. P.S.S. is supported by the Intramural Program of the National Cancer Institute, USA.
References (24)
- et al.
Estimates of the cancer incidence and mortality in Europe in 2006
Ann Oncol
(2007) The war on cancer
Lancet
(1996)Local control and patient survival
Int J Radiat Oncol Biol Phys
(1992)Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer
Clin Colorectal Cancer
(2004)- et al.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Lancet
(2007) - et al.
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
Cancer Cell
(2009) - et al.
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
Cancer Cell
(2009) - et al.
Bisphosphonates for the treatment and prevention of metastatic bone disease
Eur J Cancer
(2010) - et al.
Cancer stemness and metastasis: therapeutic consequences and perspectives
Eur J Cancer
(2010) - et al.
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth
Eur J Cancer
(2010)
Flat-panel detector-based volume computed tomography: a novel 3D imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model
Neoplasia
(2007)
Metastasis: a therapeutic target for cancer
Nat Clin Pract Oncol
(2008)
Cited by (0)
Published by Elsevier Ltd.